Efeitos da suplementação de urolitina A no metabolismo da glicose em adultos saudáveis com 55 >= anos de idade: um ensaio clínico randomizado triplo-mascarado e controlado
Os efeitos da suplementação de urolitina A no metabolismo da glicose em adultos saudáveis> = 55 anos. Um ensaio clínico randomizado triplo-mascarado e controlado
Background:
As people age, the cells in the pancreas that produce insulin begin to release less of this hormone, and levels of blood glucose (sugar) rise. This can lead to illnesses such as diabetes. Urolithin A (UA) is a natural nutritional supplement that may improve how the body controls blood glucose.
Objective:
To learn if UA improves levels of insulin and other hormones that help control blood glucose.
Eligibility:
People aged 55 years and older with a body mass index of 27 or higher.
Design:
Participants will have 6 clinic visits over 8 weeks.
Participants will be screened. They will have a physical exam with blood and urine tests and a test of their heart function.
UA gelcaps are taken by mouth every morning at home. Half of participants will take UA. The other half will take a placebo. The placebo looks like the study drug but does not contain any medicine. Participants will not know which they are taking.
Participants will have tests during the study including:
Oral glucose tolerance: Participants will drink a sweet liquid. Blood will be drawn at intervals over the next 3 hours.
Continuous glucose monitor: A sensor with a needle that goes just under the skin will be placed on the upper arm. Participants will wear this sensor throughout the study.
Exercise. Participants will walk on a treadmill while their heart rate, hearth rhythm, and blood pressure are monitored. They will walk in a hallway at normal and fast paces.
Imaging scans of the thigh; scans of the brain are optional....
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Study Description:
We hypothesize that supplementation with the nutritional supplement urolithin A (UA) in healthy adults >= 55 years old will; (i) increase insulin secretion by boosting beta cell metabolism of glucose, resulting in increased ATP generation as pyruvate enters the TCA cycle after glycolysis, thereby enhancing early, acute insulin secretion and glucose uptake in skeletal muscle -both of which will lower circulating levels of blood glucose, (ii) boost production and secretion of incretin hormones because their secretion is also dependent on cellular depolarization, (iii) boost mitochondrial function in brain and muscle tissues. (iv) alter gut microbiome. These effects will be examined over an 8-week period. The study will include a Screening Visit and 5 additional study visits.
Objectives:
Primary Objective:
To determine if UA supplementation will increase the rate at which beta cells respond to glucose.
Secondary Objectives:
Investigate if UA alters incretin secretion in response to oral glucose (incretins are secreted only in response to nutrients) and uncover if UA increases brain and skeletal muscle metabolism.
Endpoints:
Primary Endpoint:
To determine if urolithin A supplementation will influence insulin secretion in response to oral glucose at 4 and 8 weeks after supplementation.
Secondary Endpoints:
- To determine if UA supplementation will increase incretin secretion in response to oral glucose at 4 and 8 weeks after the supplementation.
- To determine if UA supplementation will enhance mitochondria respiration, based on p31 spectroscopy by thigh MRI/MRS at baseline and 8 weeks after supplementation.
- To determine if UA will increase brain oxidative metabolism, based on brain MRS at baseline and 8 weeks after supplementation.
- To determine if UA supplementation will alter gut microbiome composition.
- To determine if Uroltihin A supplementation alters the percentage of immune cell types.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Josephine M Egan, M.D.
- Número de telefone: (410) 558-8414
- E-mail: eganj@mail.nih.gov
Estude backup de contato
- Nome: Denise L Melvin, R.N.
- Número de telefone: (410) 350-3924
- E-mail: melvinde@mail.nih.gov
Locais de estudo
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- Recrutamento
- National Institute of Aging, Clinical Research Unit
-
Contato:
- Josephine Egan, M.D.
- Número de telefone: 410-558-8414
- E-mail: eganj@mail.nih.gov
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availably for the duration of the study.
- Male or female, age >= 55 years.
- Able to speak and read English. (We do not have ready access to interpreters of different languages at the NIA Clinical Unit).
- BMI >= 27.
- Ability to take oral medication and be willing to adhere to the daily regimen.
- Ability to perform walking and treadmill tests without physical limitations.
- In good general health, as evidenced by medical history/physical exam/laboratory results.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
- History of diabetes requiring treatment with any glucose lowering drug(s).
- Fasting glucose >= 126 on screening visit.
- Is on treatment with an investigational drug or other intervention within 8 weeks of enrollment.
- Hospitalization within 12 months for myocardial infarction, coronary revascularization or bypass surgery or stroke.
- History of autoimmune disease, e.g., Hashimoto s thyroiditis, Myasthenia Gravis or Rheumatoid Arthritis.
- Uncontrolled thyroid disease.
- Chronic liver disease indicated by medical history or one of the liver enzymes greater than 2 times the normal range.
- History of chronic kidney disease or GFR <60 mL/min/1.73 m^2.
- Anemia (defined as hemoglobin level <12 g/dl for men or < 11 g/dl for women).
- Poor venous access.
- Uncontrolled hypertension as judged by the Investigator.
- History of significant GI disease, e.g., IBS, Crohn s disease.
- Active cancer or has had treatment for cancer in the last 1 year.
- Medical condition requiring absolute and continuous need for long-term treatment with antibiotics, corticosteroids, immunosuppressors.
- Currently pregnant or a nursing mother due to possible changes in hormones and metabolism.
- History of, or laboratory evidence of HIV virus infection at Screening Visit.
- History of, or laboratory evidence of Hepatitis B or C at Screening Visit.
- Positive urine drug screen at Screening Visit (unless taking prescribed medication and at the discretion of the PI).
- Reports claustrophobia and/or is not eligible to have an MRI as per the MRI eligibility form.
- Weight >= 300 lbs (MRI scanner weight limit).
- Hip or knee replacement or other medical condition that prevents MRI research scans from being performed.
- Diagnosed with cognitive impairment that clearly prevents the participant from providing informed consent.
- Current smoker or tobacco use in the past year.
- History of substance abuse, including marijuana use in the past year.
- On average, consumes more than 1 alcoholic drink per day.
- Any other condition which in the investigator s opinion may adversely affect the subject s ability to complete the study or its measures or which may pose significant risk to the subject.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
50% of participants |
The placebo will consist of methylcellulose and will appear identical to the active supplement. The placebo will be provided by the manufacturer of Urolithin A. |
|
Comparador Ativo: Urolithin A
50% of participants |
Urolithin A (UA) is a widely available dietary supplement devoid of any known sided effects that is reported to improve mitochondrial function. The UA substance used in this investigation is regulated under Generally Recognized as Safe (GRAS) by the US FDA (GRN No. 000791) (https://www.fda.gov/media/120300/download) and is being advertised and sold as an oral supplement. The daily dose (1 gram) and duration (8 weeks) have already been tested in previous clinical trials. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To determine if urolithin A supplementation will influence insulin secretion in response to oral glucose at 4 and 8 weeks after supplementation.
Prazo: 8 weeks
|
Study visits 1 - 5 |
8 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To determine if UA supplementation will increase incretin secretion in response to oral glucose at 4 and 8 weeks after the supplementation.
Prazo: 8 weeks
|
Study visits 1 - 5 |
8 weeks
|
|
To determine if UA supplementation will enhance mitochondria respiration, based on p31 spectroscopy by thigh MRI/MRS at baseline and 8 weeks after supplementation.
Prazo: 8 weeks
|
Study visits 1 & 5 |
8 weeks
|
|
To determine if UA will increase brain oxidative metabolism, based on brain MRS at baseline and 8 weeks after supplementation.
Prazo: 8 weeks
|
Study visits 1 & 5 |
8 weeks
|
|
To determine if UA supplementation will alter gut microbiome composition.
Prazo: 8 weeks
|
Study visits 1, 3 & 5 |
8 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Josephine M Egan, M.D., National Institute on Aging (NIA)
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 10001930
- 001930-AG
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .